Innovative Bispecific Nanobody Targeting CD47 and CLDN18 for Advanced Colorectal Cancer Therapy
VHH-P441 is a fully humanized bispecific nanobody designed to target both CD47 molecule (CD47) and claudin 18 (CLDN18), two pivotal proteins involved in tumor immune evasion and cell adhesion, respectively. Currently in Biological Testing, VHH-P441 is positioned as a next-generation immunotherapeutic candidate for colorectal cancer. By leveraging a dual-targeting approach, this agent aims to overcome resistance mechanisms typically observed in colorectal tumors and provide more durable therapeutic responses, opening new avenues in cancer immunotherapy.
| Candidate | VHH-P441 |
| Target | CD47 molecule (CD47) claudin 18 (CLDN18) |
| Modality | humanized bispecific VHH |
| Indication | Colorectal Cancer |
Licensing Opportunity
VHH-P441 is currently available for out-licensing and partnership opportunities. We welcome inquiries from commercial partners seeking innovative bispecific nanobody therapeutics for colorectal cancer.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P441 |
Modality
VHH-P441 is an engineered bispecific antibody that integrates a single-domain antibody (nanobody) specific to the human CLDN18.2 isoform, connected via a flexible (G4S)2 linker to the C-terminal CH3 domain of a humanized monoclonal IgG1 kappa antibody aimed at CD47. Produced in Chinese hamster ovary cells, it combines the high tissue-penetration, stability, and reduced immunogenicity inherent to nanobody structures with the effector functions of a conventional antibody. This architectural advantage enhances the potential to localize at tumor sites and disrupt key signaling pathways important in colorectal cancer, supporting superior tumor targeting and therapeutic benefit.
Target
CD47 is a cell surface protein widely involved in regulating immune responses by delivering inhibitory signals that enable tumor cells to escape phagocytosis. In colorectal cancer, CD47 is commonly overexpressed, supporting tumor immune evasion. CLDN18 is a tight junction transmembrane protein predominately found in gastrointestinal tissues and frequently aberrantly expressed in colorectal cancer cells, contributing to malignancy progression. As targets, CD47 and CLDN18 offer a compelling therapeutic mechanism: CD47 blockade can enhance immune-mediated tumor clearance, while CLDN18 targeting improves selectivity by localizing treatment to tumor cells. Targeting both CD47 and CLDN18 via VHH-P441 affords strategic value by simultaneously modulating immune checkpoints and tumor-specific cell adhesion, thus representing a promising approach for overcoming therapeutic resistance in colorectal cancer.
Mechanism of Action
VHH-P441 exerts its antitumor effect through simultaneous targeting of CD47 and CLDN18. By binding CD47, the molecule disrupts inhibitory signals that prevent macrophage-mediated phagocytosis, effectively enhancing innate immune clearance of tumor cells. Concurrent engagement of CLDN18 enables precise targeting of malignant colorectal tissues, improving the selectivity and therapeutic index of immune checkpoint inhibition. The bispecific nanobody structure also supports future expansion into antibody-drug conjugate or bispecific T-cell engager platforms. Overall, VHH-P441’s mechanism offers synergistic potential for robust antitumor responses within the tumor microenvironment.
Colorectal Cancer
Colorectal cancer is among the most common malignancies globally, particularly prevalent in developed regions. Its development is associated with both genetic predisposition and lifestyle factors. Current standard treatments include surgery, chemotherapy, radiotherapy, and targeted therapies focusing on various signaling pathways and tumor markers. Although outcomes have improved, a significant proportion of patients with advanced or metastatic disease experience relapse or resistance to therapy, reflecting substantial unmet clinical needs. Limitations include tumor heterogeneity, development of drug resistance, and immune evasion mechanisms. By simultaneously targeting CD47 and CLDN18, VHH-P441 introduces a synergistic immunotherapeutic strategy, potentially enhancing tumor selectivity and immune-mediated elimination. This positions VHH-P441 as a promising candidate to address the critical gaps in colorectal cancer management and improve patient outcomes.